Demographic/baseline information for all patients who received tisagenlecleucel and unique subgroups within recipients with ALL- and NHL-specific characteristics
| . | ALL (n = 255) . | NHL (n = 155) . |
|---|---|---|
| Age at infusion, y | ||
| Median | 13.2 | 65.4 |
| Range | 0.41-26.17 | 18.45-88.99 |
| Sex, n (%) | ||
| Male | 150 (58.8) | 91 (53.5) |
| Female | 105 (41.2) | 64 (41.3) |
| Disease status at time of cellular therapy infusion, n (%) | ||
| Primary refractory/relapsed | 159 (62.3) | 147 (94.8) |
| CR | 95 (37.2) | 7 (4.5) |
| Unknown | 1 (0.5) | 1 (0.7) |
| No. of prior therapies | ||
| Median | 3 | 4 |
| Range | 0-15 | 0-11 |
| Prior HCT, n (%) | ||
| Allogeneic | 71 (27.8) | 5 (3.2) |
| Autologous | 1 (0.4) | 40 (25.8) |
| Both | 1 (0.4) | 1 (0.6) |
| Karnofsky/Lansky performance status before cellular therapy, n (%) | ||
| 90-100 | 174 (68.2) | 58 (37.4) |
| 80 | 37 (14.5) | 48 (31) |
| <80 | 31 (12.2) | 31 (20) |
| Not reported | 13 (5.1) | 18 (11.6) |
| Time from leukapheresis acceptance to infusion, d | ||
| Median | 33 | 31.5 |
| Range | 21-91 | 22-130 |
| Time of follow-up since infusion, mo | ||
| Median | 13.4 | 11.9 |
| Range | 3.5-27.9 | 3.8-19.0 |
| ALL-specific characteristics, n (%) | ||
| Age <3 y | 15 (5.9) | — |
| Down syndrome | 12 (4.7) | — |
| Prior CNS involvement | 24 (9.4) | — |
| Prior blinatumomab | 38 (14.9) | — |
| Prior inotuzumab | 27 (10.6) | — |
| MRD− before infusion | 44 (17.3) | — |
| NHL-specific characteristics, n (%) | ||
| Age ≥65 y | — | 83 (53.5) |
| Double/triple hit | — | 17 (11) |
| Transformed lymphoma | — | 42 (27.1) |
| . | ALL (n = 255) . | NHL (n = 155) . |
|---|---|---|
| Age at infusion, y | ||
| Median | 13.2 | 65.4 |
| Range | 0.41-26.17 | 18.45-88.99 |
| Sex, n (%) | ||
| Male | 150 (58.8) | 91 (53.5) |
| Female | 105 (41.2) | 64 (41.3) |
| Disease status at time of cellular therapy infusion, n (%) | ||
| Primary refractory/relapsed | 159 (62.3) | 147 (94.8) |
| CR | 95 (37.2) | 7 (4.5) |
| Unknown | 1 (0.5) | 1 (0.7) |
| No. of prior therapies | ||
| Median | 3 | 4 |
| Range | 0-15 | 0-11 |
| Prior HCT, n (%) | ||
| Allogeneic | 71 (27.8) | 5 (3.2) |
| Autologous | 1 (0.4) | 40 (25.8) |
| Both | 1 (0.4) | 1 (0.6) |
| Karnofsky/Lansky performance status before cellular therapy, n (%) | ||
| 90-100 | 174 (68.2) | 58 (37.4) |
| 80 | 37 (14.5) | 48 (31) |
| <80 | 31 (12.2) | 31 (20) |
| Not reported | 13 (5.1) | 18 (11.6) |
| Time from leukapheresis acceptance to infusion, d | ||
| Median | 33 | 31.5 |
| Range | 21-91 | 22-130 |
| Time of follow-up since infusion, mo | ||
| Median | 13.4 | 11.9 |
| Range | 3.5-27.9 | 3.8-19.0 |
| ALL-specific characteristics, n (%) | ||
| Age <3 y | 15 (5.9) | — |
| Down syndrome | 12 (4.7) | — |
| Prior CNS involvement | 24 (9.4) | — |
| Prior blinatumomab | 38 (14.9) | — |
| Prior inotuzumab | 27 (10.6) | — |
| MRD− before infusion | 44 (17.3) | — |
| NHL-specific characteristics, n (%) | ||
| Age ≥65 y | — | 83 (53.5) |
| Double/triple hit | — | 17 (11) |
| Transformed lymphoma | — | 42 (27.1) |
CNS, central nervous system.